Strong BCL2 expression in Burkitt lymphoma is not uncommon in adults

Pervez, Shahid; Raza, Muhammad Raheel; Mirza, Arslan; Pal, Anam

doi:10.4103/0377-4929.81599

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gain of 18q21 encompassed MALT1, BCL2, and TCF4 and had corresponding upregulated mRNA and/or mutation. BCL2 protein/mRNA expression was higher in adult BL, consistent with earlier studies, 53 and co-occurred with MCL1 (1q21 gain) another antiapoptotic protein. BL cell lines were more sensitive to a pan-BCL2 inhibitor (Sabutoclax) than to agents targeting single BCL2 family members, suggesting a potential target in adult BL.…”

Section: Discussionsupporting

confidence: 91%

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Bouska

Lone

et al. 2017

Blood

View full text Add to dashboard Cite

The adult high-grade B-cell lymphomas sharing molecular features with Burkitt lymphoma (BL) are highly aggressive lymphomas with poor clinical outcome. High-resolution structural and functional genomic analysis of adult Burkitt lymphoma (BL) and high-grade B-cell lymphoma with BL gene signature (adult-molecularly defined BL [mBL]) revealed the MYC-ARF-p53 axis as the primary deregulated pathway. Adult-mBL had either unique or more frequent genomic aberrations (del13q14, del17p, gain8q24, and gain18q21) compared with pediatric-mBL, but shared commonly mutated genes. Mutations in genes promoting the tonic B-cell receptor (BCR)→PI3K pathway ( and ) did not differ by age, whereas effectors of chronic BCR→NF-κB signaling were associated with adult-mBL. A subset of adult-mBL had translocation and mutation and elevated mRNA and protein expression, but had a mutation profile similar to mBL. These double-hit lymphomas may have arisen from a tumor precursor that acquired both and translocations and/or () mutation. Gain/amplification of and its paralogue loci was observed in 50% of adult-mBL. In vitro studies suggested's role in constitutive activation of BCR signaling and sensitivity to ibrutinib. Overall integrative analysis identified an interrelated gene network affected by copy number and mutation, leading to disruption of the p53 pathway and the BCR→PI3K or NF-κB activation, which can be further exploited in vivo by small-molecule inhibitors for effective therapy in adult-mBL.

show abstract

Section: Discussionsupporting

confidence: 91%

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Bouska

Lone

et al. 2017

Blood

View full text Add to dashboard Cite

show abstract

“…Particularly, increased expression of antiapoptotic Bcl-2 family members and/or reduced expression of specific proapoptotic members are typical features of B cell lymphomas [ 35 ]. Pervez et al [ 36 ] demonstrated strong diffuse cytoplasmic staining for Bcl-2 in specimens taken from an adult patient diagnosed with BL.…”

Section: Discussionmentioning

confidence: 99%

Effect of Meloxicam on the Proliferation and Apoptosis of the Raji Cell Line: an In Vitro Study

Asmarani

Supriatno

Haniastuti

2022

International Journal of Dentistry

View full text Add to dashboard Cite

Meloxicam, a nonsteroidal anti-inflammatory drug, inhibits the production of PGE2 by blocking Cox-2 activity. Specific inhibition of Cox-2 can be useful in cancer therapy by apoptosis stimulation. The objective of the research was to study the effect of meloxicam on the proliferation and apoptosis of Raji cell lines. Burkitt lymphoma (BL) cells (Raji ATCC CCL-86) were treated with various concentrations of meloxicam for 24 hours. The proliferation of the cells was evaluated by using an MTT assay. Cell apoptosis was assessed using flow cytometry, and SEM was performed to observe the morphological changes of the cells. Results showed that meloxicam affected Raji cell proliferation as well as cell apoptosis. The percentage of viable cells was decreased significantly after being treated with meloxicam ( p < 0.05 ). Apoptotic cell percentage was higher in the groups treated with meloxicam compared to the control group ( p < 0.05 ). SEM showed morphological changes in the Raji cells after treatment with meloxicam, showing apoptotic characteristics. These findings suggest that meloxicam has anticancer properties by inhibiting Raji cell proliferation and inducing Raji cell apoptosis in vitro. A combination of meloxicam with chemotherapy agents may improve the outcome of BL treatment.

show abstract

“…The tumors display the typical histological features of Burkitt's lymphoma and are markedly positive for EBV. Weak BCL2 expression is still compatible with the diagnosis of Burkitt's lymphoma [4]. Contrary to common belief, strong BCL2 IHC expression is possible in typical Burkitt's lymphoma in adults and cannot be absolutely relied upon to distinguish between Burkitt's lymphoma and DLBCL [5].…”

Section: Discussionmentioning

confidence: 99%

Burkitts Lymphoma Presenting as Late-Onset Posttransplant Lymphoproliferative Disorder following Kidney and Pancreas Transplantation: Case Report and Review of the Literature

Naik¹,

Tayapongsak

Robbins

et al. 2013

Case Rep Oncol

View full text Add to dashboard Cite

Posttransplant lymphoproliferative disorders (PTLD) are a rare, but serious complication following transplantation. Late-onset PTLD are often associated with more monoclonal lesions and consequently have a worse prognosis. There are only isolated case reports of Burkitt’s lymphoma presenting as PTLD. We present an extremely rare, aggressive Burkitt’s lymphoma years after kidney and pancreas transplantation which was successfully treated with combination chemotherapy along with withdrawal of immunosuppression. The patient remains in complete remission more than 2 years after his diagnosis. We also provide a succinct review of treatment of various PTLD and discuss the role of Epstein-Barr virus infection in the pathogenesis of PTLD.

show abstract

Strong BCL2 expression in Burkitt lymphoma is not uncommon in adults

Abstract: It was concluded that contrary to the common belief, strong BCL2 IHC expression is possible in typical BL in adults and cannot be absolutely relied upon to distinguish between BL and DLBCL.

Cited by 7 publications

References 0 publications

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Effect of Meloxicam on the Proliferation and Apoptosis of the Raji Cell Line: an In Vitro Study

Burkitts Lymphoma Presenting as Late-Onset Posttransplant Lymphoproliferative Disorder following Kidney and Pancreas Transplantation: Case Report and Review of the Literature

Contact Info

Product

Resources

About

Strong BCL2 expression in Burkitt lymphoma is not uncommon in adults

Abstract: It was concluded that contrary to the common belief, strong BCL2 IHC expression is possible in typical BL in adults and cannot be absolutely relied upon to distinguish between BL and DLBCL.

Cited by 7 publications

References 0 publications

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Effect of Meloxicam on the Proliferation and Apoptosis of the Raji Cell Line: an In Vitro Study

Burkitts Lymphoma Presenting as Late-Onset Posttransplant Lymphoproliferative Disorder following Kidney and Pancreas Transplantation: Case Report and Review of the Literature

Contact Info

Product

Resources

About

Burkitts Lymphoma Presenting as Late-Onset Posttransplant Lymphoproliferative Disorder following Kidney and Pancreas Transplantation: Case Report and Review of the Literature